PTK2 and neoplasm: Interestingly, FAK inhibitor could also upregulate PD-L1 expression on non-immune cells (CD45−PD-L1+, Additional file 6: Fig. S4B), implying a potential synergetic anti-tumor effect with anti-PD-1 antibody.